Ana Limon Carrera, Takeda Oncology, shares TAK-931 – A CDC7 Inhibitor in Solid Tumors | Dosage Collision Study Shows Treatment is Tolerable at Annual Meeting 2018
TAK-931 – A CDC7 Inhibitor in Solid Tumors | Dosage Collision Study Shows Treatment is Tolerable
